univers coverag
calendar event
medacorp puls call walk away hospit drug chain trump speech
set drug price potenti new edt
medacorp puls call get root dental distribut edt
fda adcom peripher central nervou system drug read-through
medic meet american urolog associ american head neck societi
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
furoscix survey suggest physician optim ahead june pdufa
outperform market cap price price target methodolog dcf
cash flow use discount rate
bottom line ahead june pdufa conduct medacorp survey
cardiologist treat heart failur hf gaug level interest scph furoscix
novel devic administ subcutan sq furosemid believ furoscix could provid
therapeut equival altern intraven furosemid allow patient diures home
therebi save hospit outpati heart clinic cost extend hospit stay believ
messag reson physician would use fairli larg number patient
believ survey feedback support assumpt furoscix peak market penetr
high-singl digit rang roughli market share estim provid survey
respond anoth notabl point survey import physician educ tool
close patient monitor least initi help drive adopt project sale
vs con vs con reiter op
physician understand valu proposit furoscix prescrib broadli
top two concern surround furoscix highlight survey physician
believ frequent patient monitor initi could help physician gain comfort prescrib
takeaway leerink day
bottom line today annual day host chairman presid ceo
sharon mate evp andrew satlin discuss on-going fda interact
lumateperon file schizophrenia placebo respons vari significantli studi
much confid bipolar depress takeaway discuss
lack regulatori requir complet open-label safeti studi nda file
impact function unblind may neg studi result
lack success antipsychot bpd offer attract opportun
partnership would like occur prior bpd approv
 takeaway leerink day
bottom line today annual day host ceo kevin hrusovski discuss
uptak neurolog rich immunoassay platform life scienc tool market
biopharma lab academ institut market estim research
diagnost deliv superior sensit detect limit vs current elisa
immunoassay standard market deriv revenu custom biopharma
biotech will pay premium highli sensit technolog biomark
assay sale current lever neurolog mix like shift evenli
qtrx sensit remain key success
benefit disproportion alzheim research fund brain initi
manag execut remain paramount success long-term outlook
takeaway leerink day
bottom line today annual day host presid ceo stephen farr
cfo michael smith evp chief develop offic gail farfel vice-president global regulatori
affair aj acker discuss sever investor controversi compani includ
upcom studi result cardiac safeti risk robust ip key takeaway
team convict studi similar first phase belief
cardiac risk truli exist confirm expect file nda dravet
syndrom later receiv prioriti review fda
epidiolex brief document came expect fda understand need
manag confid method treatment ip
management focus lt valu creation driven etrasimod ralinepag
bottom line ralinepag pulmonari arteri hypertension/pah link etrasimod ulcer
colitis/uc link gener strong data meet today management provid addit
context keep us optimist asset advanc although data pain
associ crohn diseas continu stock momentum near-term arena focus
valu creation lead program long term support strong cash balanc
arena introduc addit program start second cardiovascular cv program
reiter op pt
management optimist reagrd etrasimod safeti profil
etrasimod posit efficaci data provid meaning read-through upcom studi
end meet could occur expedit crohn develop timelin possibl
contemporan studi maxim ralinepag valu pah could also gener multipl data
catalyst
data on-track link could anoth meaning asset partner
recent equiti rais creat strong cash buffer studi sight second cv program initi
kol address controversi ahead storm data
bottom line clinical-stag biotechnolog compani focus develop small molecul
oral cancer drug call select inhibitor nuclear export sine differenti
mechan compar drug market develop treatment cancer
kpti lead molecul selinexor evalu two potenti registration-en phase ii trial
top-lin data expect year phase iib storm trial penta-refractori multipl myeloma
patient phase iib sadal trial relapsed/refractori diffus larg b-cell lymphoma r/r dlbcl
patient ahead upcom storm top-lin data penta-refractori multipl myeloma expect
shortli end april spoke two medacorp kol highlight view
selinexor opportun controversi selinexor multipl myeloma describ within
selinexor storm top-lin data penta-refractori multipl myeloma expect end april
recal storm phase iib studi evalu selinexor low dose dexamethason
takeaway kol convers
takeaway leerink day
bottom line today annual day host ceo chairman greg went
discuss adama uniqu biolog approach on-going launch extend releas
amantadin product gocovri parkinson diseas dyskinesia addit discuss investor
controversi surpris entri second extend releas amantadin formul osmolex
gocovri prospect multipl sclerosi walk ms walk import takeaway
adama plan report data eas open label extens studi day
belief gocovri could target subject respond ampyra ms walk
takeaway leerink day
bottom line today annual day host ceo presid paul bolno
discuss compani uniqu approach anti-sens oligonucleotid aso therapi recent
announc takeda collabor thought huntington data competitor
ioni roch wave remain differenti highli specifc approach oligonucelotid
therapi clinic data next month could valid benefit platform
altern methodolog
bottom line arql host confer call discuss recent derazantinib arq fgfr
inhibitor licens agreement basilea pharmaceutica link data present american
associ cancer research annual meet link provid updat clinic
strategi updat model reflect derazantinib deal updat financi guidanc
recal recent announc agreement basilea obtain right derazantinib us
eu japan rest world exclud china hong kong macau taiwan exchang
up-front regulatori commerci mileston arql also elig receiv
stagger single-digit double-digit royalti net sale upon commerci call arql
guid end cash vs previous suffici fund oper
continu view deal favor given investor concern compani cash
posit extend cash runway also fund compani past key valu inflect point maintain
posit view stock ahead multipl clinic catalyst expect among arql
pipelin continu view arq revers inhibitor wild type mutant btk
excit sourc signific upsid stock indic arq could play
role chronic lymphocyt leukemia cll remain dynam competit medacorp kol
check highlight potenti arq link see potenti long-term appreci arq
becom de-risk clinic updat next clinic updat expect eha
year reiter op pt
revenu present million ep
quick strong oper growth qtr high
bottom line deliv anoth solid quarter ep beat us
consensu penni come high end manag guidanc
rang key us less ep sale growth perform
deliv strong oper sale growth across divis deliv organ sale growth
believ investor expect may limit upsid
share today despit otherwis good quarter think stock reaction
predic commentari tone post-earn confer call
expect posit highlight acceler growth upsid potenti number new
product launch us remain execut stori compani integr recent
major acquisit drive new product cycl medic devic busi steadi
turnaround nutrit busi quarter perform seem posit data point
support view success execut
showcas strength biz model posit read-across group new
 methodolog base price-to-earnings ep
bottom line rais pt post strong report showcas
strength busi model re-instil confid offer favor read-
across group expect continu earn upsid rais
ep back solid quarter thirteen percent top-lin adj ep growth yoy
continu showcas strength busi model synergist across optum
uhc optum optum insight grow solid doubl digit optum rx yoy rx
script growth expand overal optum margin bp yoy within uhc medicar
remain strongest growth segment though commerci growth expect pick
multipl price-to-earnings forward ep expand recent news-flow
enter hospit drug suppli chain entrench competit logist challeng similarli
drug suppli chain price reform pois manifest tame rfi hh
schedul speech rx drug price presid trump april also like drive generalist
money sidelin
revenu billion ep dilut show ep exclud non-cash
amort year quarterli number may sum full-year number due round
transit analyt value-bas continu
first vasostrict anda file come surpris
aacr poster highlight addit tipifarnib opportun
outlook move higher still conserv
 methodolog ep
aacr wrap-up genom demand strong liquid biopsi benefit
price commerci updat fda approv burosumab/
analysi discount rate termin growth
epidiolex brief doc signal posit risk/benefit
machine-lik multipl new prod cycl pt
 methodolog dcf wgtd average cost capit
hcit distribut transit analyt value-bas continu
 like posit catalyst conserv guidanc
medic suppli devic individu co preview ortho supplies/cap equipment/
medic suppli devic individu co preview cardio large-cap diversifi
next import catalyst alder extend follow-up data two ph
pivot trial chronic migrain sever episod migrain
american academi neurolog annual meet
two trial expect provid extend durat repeat dose safeti
efficaci month month
data expect includ bla eptinezumab need
consist earlier announc trial data free
increas new advers event increas neutral antibodi
storm phase ii studi selinexor penta-refractori multipl myeloma mm
full interim storm result selinexor low-dos dexamethason dex first
patient highlight drug single-ag activ difficult-to-treat patient --
management believ bode well approv probabl drug
prior data indic solid activ orr overal respons rate across
variou subgroup quad penta-refractori pt
expans cohort addit penta-refractori mm patient expect
top-lin data orr primari endpoint end april
believ selinexor could potenti address peak us sale opportun
risk-adjust multipl myeloma
event posit data manag plan submit nda
may genesight data present pharmacogenom test
believ data present american psychiatr associ confer
provid insight secondari genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
may dova pdufa avathombopag thrombocytopenia chronic liver
fda accept avatrombopag nda prioriti review treatment
thrombocytopenia patient chronic liver diseas cld schedul undergo
presum regul valid dova high degre confid
approv applic basi trial well studi
conduct indic
compani plan immedi launch june approv begun hire
key sale staff includ head us sale deep experi liver diseas drug
dova also remain track complet regulatori submiss ema approv
indic
addit cld indic dova explor label expans opportun broader
pre-surgeri popul thrombocytopenia patient chemotherapy-induc
dova believ opportun tripl size avatrombopag address market
june american societi clinic oncolog
year updat patient treat combin lead
candid mirvetuximab soravtansin avastin
result includ data dose-expans cohort -- patient
avastin-na previous receiv avastin
line treatment set avastin-na pt avastin previous gener
median progression-fre surviv mpf chemotherapi well
expect topic jak inhibitor ph ii top-lin data alopecia areata
aa us studi patient one month durat could demonstr
earli valid topic jak inhibitor approach
also develop topic jak janu kinas inhibitor patchi hair loss
possibl androgenet alopecia aga aka male/femal pattern bald
success would open anoth multi-billion dollar market
compani jak inhibitor program treatment immune-medi hair loss
disord aa core upsid driver model account
even use conserv assumpt believ oral jak inhibitor could achiev peak
annual sale aa alon
ph ii top-lin data australia eyebrow studi patient
view agent novel chemic structur avoid format presum toxic
metabolit good reason atogep could avoid liver toxic seen
telcagep follow-on compound
support view gen molecul calcitonin gene-rel peptid cgrp
may avoid liver safeti risk management report un-blind look liver enzym
elev agn on-going atogep studi line placebo event rate
clinic studi
atogep deliv efficaci profil within strike distanc inject
good safeti toler work suggest sizabl market opportun base
inject categori oral late entrant xeljanz rheumatoid arthriti otezla
psoriasi
believ program good chanc success view success
atogep migrain prevent would offer signific valid agn open-sci
bold ph i/ii x-link myotubular myopathy/xlmtm
audent expect announc updat phase i/ii aspiro data
possibl american societi gene cell therapi confer may
also expect phase i/ii valen data possibl european societi
pediatr gastroenterolog hepatolog nutrit meet may
though small earli natur believ set data
help valid compani gene therapi platform draw investor interest
compani subsequ earlier stage candid like catecholaminerg
polymorph ventricular tachycardia/cpvt pomp diseas
celg ph trial revlimid follicular lymphoma
augment trial approach complet top-lin result releas earli
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
scph lead asset furoscix at-hom diuresi anticip pdufa action date
manag see signific opportun furoscix reduc patient admiss day
hospit acceler patient discharg reduc readmiss rate
continu believ furoscix subcutan administr gain strong earli
adopt hospital-bas event drive iv furosemid use market
iv diuresi iv furosemid
believ furoscix provid strong pharmacoeconom incent move care
high cost hospit set at-hom set
continu see odd success approv forecast
sale sale
initi furoscix heart failur health econom outcom research studi
june akao pdufa plazomicin gram neg infect
decemb akao report posit top-lin data two phase studi epic
expect support registr expect primari driver
commerci adopt
epic recruit patient suspect complic urinari tract infect cuti
demonstr plazomicin statist non-inferior meropenem fda primari
endpoint statist superior three key efficaci measur includ ema
primari outcom test cure
see nich role plazo treatment-refractori cuti expect drug
primari clinic util carbapenem-resist enterobacteriacea support
compel data studi albeit small sampl show
reduct death/seri complic mortal respect rel
activ control
continu project peak sale plazomicin ww us sale
row royalti us sale come
fda adcom meet may believ like vote
approv plazomicin along indic bloodstream infect caus certain
compani anticip report ph ii proof-of-concept data
management state observ reduct level -- marker glycem control
dose depend
compani anticip observ dose respons biomark reflect
drug mechan action
goal would posit agent line difficult-to-treat patient use
glycem control compani see potenti market appli
probabl success
model gross sale
believ investor expect head ph ii/iii data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
luspatercept phase data md beta-thalassemia
ph trial readout xlrn lead asset luspatercept lower-risk myelodysplast
syndrom md medalist trial transfusion-depend beta thalassemia believ
trial around mid-year signific event investor acceleron stock
recent meet xlrn manag team clearli confid
abil luspatercept duplic ph ii result on-going ph studi
manag believ data trial avail within week two
unclear result disclos posit like
project ww probability-weight p/w luspatercept lower-risk md sale
royalti beta thalassemia project p/w ww sale
royalti
updat luspatercept ph ii dataset like european hematolog
sourc leerink research compani inform factset price prior day
fda adcom peripher central nervou system drug read-through
fda adcom arthriti drug safeti risk manag
presid trump speak drug price reform hh secretari deliv
keynot health datapalooza
fda adcom brief document antimicrobi drug plazomicin akao
fda adcom brief document gastrointestin drug pediatr
fda adcom antimicrobi drug plazomicin akao
fda adcom gastrointestin drug pediatr stannsoporfin infect
fda adcom endocrinolog metabol drug
pdufa dova avatrombopag thrombocytopenia chronic liver diseas
pdufa akao plazomicin complic urinari tract infect bloodstream
pdufa dupix moder sever asthma adult adolesc
pdufa revefanacin lama copd
american head neck societi combin otolaryngolog spring meet
american societi androlog
european congress clinic microbiolog infecti diseas
american academi neurolog aldr
nation foundat infecti diseas annual confer vaccin
american societi aesthet plastic surgeri
american congress obstetrician gynecologist
american associ neurolog surgeon
american associ thorac surgeri
american colleg occup environment medicin
associ research vision ophthalmolog nite
american societi pediatr hematology/oncolog
intern societi cellular therapi
american societi breast surgeon
american associ immunologist
pan american societi clinic virolog
european societi pediatr gastroenterolog hepatolog nutrit
societi biolog psychiatri
societi pediatr radiolog
abstract releas edt
societi investig dermatolog
american societi gene cell therapi
american associ clinic endocrinologist
societi neurolog surgeon
world feder hemophilia
european academi allergi clinic immunolog
trump deliv speech drug price reform hh secretari deliv keynot
health datapalooza
hcit distribut transit analyt value-bas continu
 like posit catalyst conserv guidanc
medic suppli devic individu co preview ortho supplies/cap equipment/
medic suppli devic individu co preview cardio large-cap diversifi
 aet creat new front healthcar outperform larsen david
manag cvs-aet neutral ep wcg ci
gupt ana
-- flash aducanumab phase trial expand variabl endpt requir
-- flash takeaway leerink global healthcar confer
 growth margin management stabil still lack pipelin catalyst market
 aducanumab titrat arm bolster evid treatment effect market perform
 ctad medacorp call aducanumab abeta hypothesi
life scienc tool diagnost -- flash fund present posit upsid nih
spend life scienc tool
 leerink confer highlight dinner manag market
 apec studi discontinu remov verubecestat model pt market
 state larg cap biotech sfo steadi goe
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
 ttr seri part handicap on-going tafamidi trial fac market
 growth deal capac target market
 set new slow-growth outlook get excit pt
biopharma praluent show mortal benefit lower take aim highest risk group
biopharma -- flash trulic sustain blow sema must show cv benefit
biopharma -- flash bydureon fail show cv benefit posit novo rewind
biopharma -- flash highlight invokana fda warn puls call modest impact
 leerink confer highlight dinner manag market
 model updat reflect goal achiev w/ pipelin success market
mdco -- flash inclisiran lesson fourier/odyssey may better
mdco anoth step forward cubist vabomer approv pt outperform
novob dc highlight nvo management roundtabl discuss boston market
novob dc evolut market make pivot year novo
biopharma -- flash highlight invokana fda warn puls call modest impact
medic suppli devic abt/mdt secur approv diabet devic
medic devic leerink healthcar confer panel devic penetr set
medic devic ada wrap-up posit meet devic podd/abt/mdt
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
novob dc -- flash near-unanim vote clear path semaglutid approv
 upgrad op convict top-lin growth accel stori pt
 ar takeaway -- -excit build ahead sinuva launch outperform
 slow growth outlook price power reced upsid limit pt
biopharma price right payer fail get drug class come
biopharma dupix approv price test new paradigm drug access
 volum price pressur continu reduc estim market perform
esrx aggress price loss competit market pt market perform
hcit distribut brand inflat top show deceler y/i
cautiou
hcit distribut fda take step improv competit distributor near trough
 respit price yet friendli hill fda could
biopharma name shame california latest strategi rein drug price
healthcar distribut suppli chain preview price volum trend appear
hcit distribut outlin possibl drug price polici draconian
fear
 elast demand consist reduc price drive volum growth
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
biopharma -- flash highlight io combin seri puls call front-lin lung
biopharma highlight io agonist checkpoint puls call updat
biopharma takeaway io remain major area focu
io clinic trial updat crossroad effici
 deep dive highlight oncolog focu strategi nash market perform
 patent fall hurdl humira cut like pipelin loom market
achn recap increment advanc patent complement progress
acr/ patent issuanc enhanc lt valu could add npv
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
 took money ranminim valu uplift us patent win market
biopharma cafc oral argument justic challeng scope ab patent
 patent issuanc reflect execut strategi pt outperform
 recap data ip progress uk/eu mark new year outperform
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
biopharma might deton event look like screen pot match-
biopharma viii partnership acquisit biopharma new top list
celg anoth bet car-t probabl probabl sensibl even
 aet bring comprehens member
cori posit updat donepezil pilot studi possibl partnership ye
dplo mid-mkt pbm acquisit complet strateg move market perform
 management highlight robust partnership program pt
 add cscc respons diseas boost /sni partnership
 increas pt takeda collabor stock weak offer oppti
 initi adama step forward parkinson dyskinesia outperform
 atop dermat still without ped leerink dupix
derm survey
 hiv survey rapid adopt biktarvi challeng outlook
gsk
 initi
hcit distribut hospit hcit survey highlight shift analyt
moat vs
 insight april nyc hc servic day convict
medic suppli devic survey direct posit
mute hope new indications/improv execut
 mylan upgrad valuat disconnect given diversifi busi catalyst
path outperform
major highlight medacorp lung cancer survey focus
nsclc
 initi could adenosin inhibit unlock wave i/o
outperform
 initi doubl digit growth meaning margin expans ahead
outperform
-- contact leerink repres detail access podcast
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
 pnh survey-soliri still grow like switch monthli sc best
biopharma atop derm still without ped leerink dupi derm survey
 pbc survey suggest ocaliva safeti concern manag
 hiv survey rapid adopt biktarvi challeng outlook
 rubraca posit base survey lower est due payer assist
hcit distribut demand shift analyt effect use
 vyxeo survey suggest outpati usag grow outperform
major medacorp survey lung cancer posit azn
limit upsid link
medic suppli devic survey flu help otherwis normal volume downtick
 physician survey support nerlynx opp ty breast cancer pt
medic devic survey direct posit mute hope
tsro ovarian cancer survey affirm parp market upgrad op improv risk/
 leerink leadership seri new product growth acceler stori market
medic devic leerink leadership seri outset drive shift dialysi self-car
medic devices-cardiolog leerink leadership seri target
outlook alpha opportun abound healthcar share
